Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352601 | 0.87 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5342624 | 0.85 | ALDH1A1 (0.48) | KDM4EALDH1A1PDCD1CD274LMNA | |
| SCHEMBL5348801 | 0.80 | CYP1A2 (0.51) | SMN1; SMN2POLBPDCD1CD274LMNA | |
| SCHEMBL5342007 | 0.78 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL1627052 | 0.77 | MEN1 (0.77) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5342091 | 0.77 | ALDH1A1 (0.64) | KDM4EALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL5339010 | 0.76 | ALDH1A1 (0.55) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11865724 | 0.74 | KDM4E (0.65) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7618274 | 0.74 | ALDH1A1 (0.72) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7226548 | 0.74 | ALDH1A1 (0.67) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 2714/4885ALDH1A1 810/4885SMN1; SMN2 1511/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 1709/4885ALDH1A1 865/4885SMN1; SMN2 869/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 2714/4885ALDH1A1 810/4885SMN1; SMN2 1511/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 2714/4885ALDH1A1 810/4885SMN1; SMN2 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.